Patent: 6,808,922
✉ Email this page to a colleague
▶ Start for $100
Remove trial restrictions
Summary for Patent: 6,808,922
| Title: | Retroviral vectors comprising a functional splice donor site and a functional splice acceptor site |
| Abstract: | A retroviral vector is described. The retroviral vector comprises a functional splice donor site and a functional splice acceptor site; wherein the functional splice donor site and the functional splice acceptor site flank a first nucleotide sequence of interest (\"NOI\"); wherein the functional splice donor site is upstream of the functional splice acceptor site; wherein the retroviral vector is derived from a retroviral pro-vector; wherein the retroviral pro-vector comprises a first nucleotide sequence (\"NS\") capable of yielding the functional splice donor site and a second NS capable of yielding the functional splice acceptor site; wherein the first NS is downstream of the second NS; such that the retroviral vector is formed as a result of reverse transcription of the retroviral pro-vector. |
| Inventor(s): | Bebbington; Christopher Robert (Berkshire, GB), Kingsman; Susan Mary (Oxon, GB), Uden; Mark (Oxon, GB), Kingsman; Alan John (Oxon, GB), Mitrophanos; Kyriacos (Oxon, GB) |
| Assignee: | Oxford Biomedica Limited (Oxford, GB) |
| Application Number: | 09/508,516 |
| Patent Claims: | see list of patent claims |
Details for Patent 6,808,922
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Sign Up | 2017-09-25 |
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Sign Up | 2017-09-25 | |
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Sign Up | 2017-09-25 | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
